Clinical Trial Update: Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 [Phase 1]

View source ↗

Summary

A Phase I open-label, dose-escalation study of AZD4877 in lymphoma and Non-Hodgkin lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• AZD4877

Snippet

Sponsor: AstraZeneca | Conditions: Lymphoma, NHL | Phase 1 | Status: TERMINATED